Company News: Merus Further Expands R&D Capacity


Thursday, March 7, 2013

- Company Contracts R&D Service Provider FairJourney Biologics -

Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has significantly expanded its capabilities to generate large collections of distinct, unique bispecific antibodies against target combinations.

Under an agreement signed with R&D service provider FairJourney Biologics, Merus will strengthen its R&D resources for selecting the most promising common light chain antibodies generated by its MeMo® transgenic mouse. These antibodies are then formatted into full-length bispecific IgG antibodies – called Biclonics™ – that can be further tested in high-throughput cell-based assays.

 

 

Leave a Reply


In order to submit a comment, you need to mention your name and your email address (which won't be published). And ... don't forget your comment!

Comment Form









More in Company News (53 of 183 articles)